If you have non-small cell lung cancer (NSCLC), your doctor will recommend PD-L1 testing. This test will help your doctor understand if you can be treated with a type of cancer drug called immune ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Background: Programmed death 1 (PD-1) and the ligand of PD-1 (PD-L1) are central targets for immune-checkpoint therapy (ICT) blocking immune evasion-related pathways elicited by tumor cells. A number ...

OLFM4 was related to T-cell malfunction and tumour-associated macrophage infiltration, leading to a worse prognosis in GBC. Further investigations revealed that OLFM4 upregulated programmed ...

Feb. 6, 2025 — A recent study investigates how polyester microdroplets, potential precursors to modern cells, could form under realistic early Earth conditions. Researchers pushed these ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Chicago PD’s Gwen Sigan teases Voight meeting his match with adversary, Reid, Torres’ turmoil, and feature-length crossover. Check it out!

aly-miR159a-3p enhances anti-PD-L1 therapy by increasing microbiota-dependent docosahexaenoic acid (DHA) level thus limiting tumor cell PD-L1 expression. Here the authors discover that ...

Recognition of specific antigen through the B-cell receptor (BCR) stimulates the activation of B cells, which ultimately results in the production of high-affinity antibodies and the provision of ...